Adagene (ADAG) H.C. Wainwright 27th Annual Global Investment Conference summary

Pipeline overview and technology platforms

• Focus on next-generation antibody therapies for cancer using proprietary NEObody, SAFEbody, and POWERbody platforms.

• Lead program ADG126 is a novel masked anti-CTLA-4 antibody with enhanced ADCC and improved therapeutic index.

• SAFEbody technology enables selective activation in tumor microenvironments, requiring both high protease concentration and target expression.

Strategic collaborations and funding

• Expanded partnership with Sanofi includes up to $25 million equity investment and $17 million received at signing.

• Collaboration covers discovery, funding for phase 2, and a trial evaluating Sanofi's bispecific antibody with ADG126 in over 100 solid tumor patients.

Clinical development and data highlights

• ADG126 can be dosed up to 20 mg/kg every six weeks, enabled by safety margin from masking technology.

• Low discontinuation rates due to toxicity, allowing multiple treatment cycles and improved patient quality of life.

• High-dose cohorts show confirmed overall response rate (ORR) of 29%, with median overall survival of 19 months at lower doses, outperforming standard of care.